Examining the Efficacy, Safety, and Future Prospects of Tirofiban in Managing Myocardial Infarction among Diabetic Patients.
Haajeera SamsudeenV P Dharani ShrinivasanPublished in: Current diabetes reviews (2024)
Tirofiban, a platelet GP IIb/IIIa receptor inhibitor, shows promise as adjunctive therapy in the emergency management of MI in diabetic patients. It has demonstrated efficacy in improving clinical outcomes, reducing myocardial ischemia-reperfusion injury, and promoting early recovery of heart function. However, healthcare providers should be cautious regarding the potential risk of tirofiban-associated thrombocytopenia. Further research is needed to optimize dosing guidelines, evaluate long-term safety, and fully understand the benefits and limitations of tirofiban in this patient population. The comprehensive insights provided in this review aim to enhance treatment strategies and improve patient outcomes in the emergency management of MI in diabetic individuals.
Keyphrases
- healthcare
- ischemia reperfusion injury
- public health
- emergency department
- heart failure
- left ventricular
- current status
- type diabetes
- oxidative stress
- case report
- atrial fibrillation
- big data
- machine learning
- social media
- emergency medical
- risk assessment
- human health
- wound healing
- binding protein
- cell therapy
- health insurance